Treatment details
| Characteristic . | FL, n (%) (n = 14) . | R/R, n (%) (n = 17) . |
|---|---|---|
| Treatment regimens* | ||
| DAC/AZA + VEN | 8 (57) | 10 (59) |
| Cladribine + LDAC + VEN | 3 (21) | 2 (12) |
| IDH1 inhibitors/IDH2 inhibitors + VEN† | 1 (7) | 1 (6) |
| CPX-351 + VEN | 1 (7) | 2 (12) |
| CLIA + VEN or FLAG (± Ida) + VEN | 1 (7) | 2 (12) |
| No. of VEN cycles | ||
| 1 cycle | 5 (36) | 6 (35) |
| 2 cycles | 3 (21) | 5 (29) |
| ≥3 cycles | 6 (43) | 6 (35) |
| VEN initial dose | ||
| ≥400 mg | 3 (21) | – |
| 200 mg with strong CYP3A4-i | 3 (21) | 4 (26) |
| 200 mg with moderate CYP3A4-i | 3 (21) | 2 (12) |
| 100 mg with strong CYP3A4-i | 5 (36) | 10 (59) |
| 50 mg with strong CYP3A4-i | – | 1 (6) |
| VEN duration reduction | ||
| During first cycle | 2 (14) | 3 (18) |
| During subsequent cycles | 6 (43) | 4 (26) |
| VEN dose reduction: during subsequent cycles‡ | 2 (14) | 2 (12) |
| Characteristic . | FL, n (%) (n = 14) . | R/R, n (%) (n = 17) . |
|---|---|---|
| Treatment regimens* | ||
| DAC/AZA + VEN | 8 (57) | 10 (59) |
| Cladribine + LDAC + VEN | 3 (21) | 2 (12) |
| IDH1 inhibitors/IDH2 inhibitors + VEN† | 1 (7) | 1 (6) |
| CPX-351 + VEN | 1 (7) | 2 (12) |
| CLIA + VEN or FLAG (± Ida) + VEN | 1 (7) | 2 (12) |
| No. of VEN cycles | ||
| 1 cycle | 5 (36) | 6 (35) |
| 2 cycles | 3 (21) | 5 (29) |
| ≥3 cycles | 6 (43) | 6 (35) |
| VEN initial dose | ||
| ≥400 mg | 3 (21) | – |
| 200 mg with strong CYP3A4-i | 3 (21) | 4 (26) |
| 200 mg with moderate CYP3A4-i | 3 (21) | 2 (12) |
| 100 mg with strong CYP3A4-i | 5 (36) | 10 (59) |
| 50 mg with strong CYP3A4-i | – | 1 (6) |
| VEN duration reduction | ||
| During first cycle | 2 (14) | 3 (18) |
| During subsequent cycles | 6 (43) | 4 (26) |
| VEN dose reduction: during subsequent cycles‡ | 2 (14) | 2 (12) |
CLIA, combination of cladribine, cytarabine, and idarubicin; FLAG ± Ida, combination of fludarabine, cytarabine ± idarubicin, and growth factor; CYP3A4-i, cytochrome P450 3A4 inhibitors (strong [eg, posaconazole or voriconazole]; moderate [eg, isavuconazole]).
Ruxolitinib or gemtuzumab ozogamicin were used in some patients, as detailed in the text.
IDH1 inhibitor was used in 1 patient in the FL setting and IDH2 inhibitor in 1 patient in the R/R setting.
These patients had concomitant reduction of duration of VEN therapy.